Merck & Co., Inc.
- MRK · NYSE
- Pharmaceutical Preparations
- Rahway, NJ
- 75,000 employees
- CIK 0000310158
Updated from SEC filings through
Top things to know
Executives
-
Robert M. Davis Chairman, CEO & President 4, 2026-05-07 -
Caroline Litchfield EVP & CFO 4, 2026-05-07 - David Michael Williams EVP,Chief Info&Digital Officer 4, 2026-08-07
-
Betty D. Larson EVP, Chief HR Officer 4, 2026-05-07 - Dean Y. Li Executive VP & President, MRL 4, 2026-05-07
- Dalton Smart Senior Vice President Finance, Global Controller 10-K, 2026-02-24
Merck & Co., Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Rahway, NJ. It trades as MRK on NYSE. Revenue was $65.0B in the fiscal year ending December 31, 2025, +1.3% from the year before. It reported about 75,000 employees. Robert M. Davis is Chairman, CEO & President.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $65.0B 10-K, 2026-02-24 | $64.2B 10-K, 2026-02-24 | $60.1B 10-K, 2026-02-24 | $59.3B 10-K, 2025-02-25 | $48.7B 10-K, 2024-02-26 |
| Operating income | Not on file | Not on file | Not on file | Not on file | Not on file |
| SG&A | $10.7B 10-K, 2026-02-24 | $10.8B 10-K, 2026-02-24 | $10.5B 10-K, 2026-02-24 | $10.0B 10-K, 2025-02-25 | $9.6B 10-K, 2024-02-26 |
| Net income | $18.3B 10-K, 2026-02-24 | $17.1B 10-K, 2026-02-24 | $365M 10-K, 2026-02-24 | $14.5B 10-K, 2025-02-25 | $13.0B 10-K, 2024-02-26 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Robert M. Davis | Chairman, CEO & President | 4, 2026-05-07 |
| Caroline Litchfield | EVP & CFO | 4, 2026-05-07 |
| David Michael Williams | EVP,Chief Info&Digital Officer | 4, 2026-08-07 |
| Betty D. Larson Executive Vice President and Chief Human Resources Officer and Board Member | EVP, Chief HR Officer | 4, 2026-05-07 |
| Dean Y. Li | Executive VP & President, MRL | 4, 2026-05-07 |
| Dalton Smart SVP Finance, Global Controller | Senior Vice President Finance, Global Controller | 10-K, 2026-02-24 |
| David M. Williams | Executive Vice President, Chief Information and Digital Officer | 10-K, 2026-02-24 |
| Dean Li | Executive Vice President, President, Merck Research Laboratories | 10-K, 2026-02-24 |
| Johannes J. Oosthuizen | Senior Vice President and President Merck U.S. Human Health | 10-K, 2026-02-24 |
| Joseph Romanelli | Senior Vice President and President MSD International Human Health | 10-K, 2026-02-24 |
| Cristal N. Downing | Chief Comm. & Public Afrs Ofcr | 4, 2025-11-12 |
| Gaurav K. Gupta EVP, Chief Information & Digital Officer at Merck | EVP, CIDO | 3, 2026-09-01 |
 Chirfi Guindo Executive Vice President, Strategic Access, Policy, & Communications | EVP, Access, Policy & Comms | 4, 2026-08-13 |
 Jennifer Zachary Currently at Merck & Co., Inc. | EVP, General Counsel | 4, 2026-08-13 |
 Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | 4, 2026-08-12 |
| David R. Maraldo | EVP & Pres. MMD | 4, 2026-08-07 |
What Merck & Co., Inc. does
, Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 2.47 billion (as of October 31, 2026) | 10-Q, November 4, 2026 |
|---|---|---|
| Public float | $198B (as of June 30, 2025) | 10-K, February 24, 2026 |
| Reportable segments | 2 (period ending September 30, 2026) | 10-Q, November 4, 2026 |
| Latest proxy statement | Meeting May 26, 2026 (filed April 8, 2026) | DEF 14A, April 8, 2026 |
| Auditor | PricewaterhouseCoopers LLP (Florham Park, New Jersey) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| August 13, 2026 | Chirfi Guindo EVP, Access, Policy & Comms | Sale | 10,000 | $1.4M | Form 4, August 13, 2026 |
| August 12, 2026 | Jennifer Zachary EVP, General Counsel | Sale | 80,315 | $10.7M | Form 4, August 13, 2026 |
| August 12, 2026 | Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Sale | 45,320 | $5.9M | Form 4, August 12, 2026 |
| August 6, 2026 | Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Sale | 6,050 | $789K | Form 4, August 10, 2026 |
| August 6, 2026 | Chirfi Guindo EVP, Access, Policy & Comms | Sale | 15,000 | $2.0M | Form 4, August 7, 2026 |
| August 5, 2026 | David R. Maraldo EVP & Pres. MMD | Sale | 18,706 | $2.4M | Form 4, August 7, 2026 |
| August 5, 2026 | David Michael Williams EVP,Chief Info&Digital Officer | Sale | 52,847 | $6.8M | Form 4, August 7, 2026 |
| February 12, 2026 | Chirfi Guindo Chief Marketing Officer | Sale | 10,000 | $1.2M | Form 4, February 12, 2026 |
Recent 8-K events
- 8-K filed 2026-10-29
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-10-13
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-08-04
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-28
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-22
- Item 8.01 Other events
- 8-K filed 2026-04-30
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-02-03
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-12-04
- Item 8.01 Other events
- 8-K filed 2025-10-30
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-09-09
- Item 8.01 Other events
Frequently asked questions about Merck & Co., Inc.
- What does Merck & Co., Inc. do?
- In its own words, from Item 1 of its 10-K: ", Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments."
- What is Merck & Co., Inc.'s revenue?
- $65.0B for the fiscal year ending December 31, 2025, from its 10-K filed February 24, 2026.
- Is Merck & Co., Inc. profitable?
- Merck & Co., Inc. reported net income of $18.3B for the fiscal year ending December 31, 2025.
- How many employees does Merck & Co., Inc. have?
- About 75,000 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Merck & Co., Inc.?
- Robert M. Davis, Chairman, CEO & President, as named in a 4 filed May 7, 2026.
- Who is the CFO of Merck & Co., Inc.?
- Caroline Litchfield, EVP & CFO, as named in a 4 filed May 7, 2026.
- Where is Merck & Co., Inc. headquartered?
- Rahway, NJ.
- What is Merck & Co., Inc.'s stock ticker?
- MRK on NYSE.
- What industry is Merck & Co., Inc. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Merck & Co., Inc.'s website?
- merck.com. Investor relations: https://www.merck.com/investor-relations/.
- When does Merck & Co., Inc. report earnings next?
- February 2, 2027. Source: ir_events.
- Is Merck & Co., Inc. a public company?
- Yes. Merck & Co., Inc. files with the SEC under CIK 0000310158 and trades as MRK.
- Who audits Merck & Co., Inc.?
- PricewaterhouseCoopers LLP, Florham Park, New Jersey, as named in its latest annual report (10-K).
- How many shares of Merck & Co., Inc. are outstanding?
- 2.47 billion shares as of October 31, 2026, from its 10-Q filed November 4, 2026.
- What is Merck & Co., Inc.'s public float?
- $198B as of June 30, 2025, as reported on the cover of its 10-K filed February 24, 2026.
- How many business segments does Merck & Co., Inc. report?
- 2 reportable segments for the period ending September 30, 2026, from its 10-Q filed November 4, 2026.
- When is Merck & Co., Inc.'s annual shareholder meeting?
- May 26, 2026, per its proxy statement (DEF 14A) filed April 8, 2026.
- Have Merck & Co., Inc. insiders traded stock recently?
- Since November 3, 2025, officers and directors reported 21 open-market sales worth about $72.0M and 0 purchases on Forms 4 and 5. The most recent: Chirfi Guindo (EVP, Access, Policy & Comms) sold 10,000 shares on August 13, 2026.